SCHEMBL3519346

SCHEMBL3519346

COc1ccccc1OCCC(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 1.00
SMN1; SMN2 Q16637 2/20 0.68
POLB P06746 1/20 0.68
MTNR1A P48039 1/20 0.58
MTNR1B P49286 1/20 0.58
L3MBTL1 Q9Y468 2/20 0.58
MAPT P10636 1/20 0.58
NPSR1 Q6W5P4 1/20 0.56
TSHR P16473 2/20 0.54
RXRA P19793 1/20 0.53
TDP1 Q9NUW8 1/20 0.51
HSD17B10 Q99714 1/20 0.51
ATM Q13315 1/20 0.51
HTR1A P08908 1/20 0.50
ADRA1D P25100 1/20 0.50
ADRA1A P35348 1/20 0.50
ADRA1B P35368 1/20 0.50
ALDH1A1 P00352 1/20 0.49
RAB9A P51151 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5319605 0.91 LMNA (0.83) LMNASMN1; SMN2POLBMTNR1AMTNR1B
SCHEMBL8355388 0.88 LMNA (0.78) LMNASMN1; SMN2POLBMTNR1AMTNR1B
SCHEMBL22434981 0.85 LMNA (0.74) LMNASMN1; SMN2POLBL3MBTL1MAPT
Hydrochloric Acid SCHEMBL9252419 0.85 LMNA (0.72) LMNASMN1; SMN2POLBMTNR1AMTNR1B
SCHEMBL7899947 0.84 LMNA (0.72) LMNASMN1; SMN2POLBMTNR1AMTNR1B
SCHEMBL10158594 0.83 LMNA (0.71) LMNASMN1; SMN2POLBMTNR1AMTNR1B
1,2-Dimethoxybenzene SCHEMBL31672175 0.82 LMNA (0.70) LMNASMN1; SMN2POLBTSHRRXRA
SCHEMBL14273052 0.82 LMNA (0.70) LMNASMN1; SMN2POLBMTNR1AMTNR1B
SCHEMBL9389543 0.82 LMNA (0.70) LMNAL3MBTL1MAPTNPSR1ALDH1A1
SCHEMBL6200067 0.81 LMNA (0.69) LMNASMN1; SMN2POLBMTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112041296-B Aminoacetamides containing benzooxy alicyclic structures and uses thereof 上海璃道医药科技有限公司 2023-12-29 CN disclosed
CN-110770211-B Alpha, beta unsaturated amide compound 协和麒麟株式会社 2023-09-19 CN disclosed
CN-108430972-B Alpha, beta-unsaturated amide compound 协和麒麟株式会社 2022-12-27 CN disclosed
US-11447471-B2 α,β-unsaturated amide compound KYOWA KIRIN CO., LTD. (JP) 2022-09-20 US disclosed
US-11332455-B2 α,β-unsaturated amide compound KYOWA KIRIN CO., LTD. (JP) 2022-05-17 US disclosed
US-20210380551-A1 ALPHA,BETA-UNSATURATED AMIDE COMPOUND KYOWA KIRIN CO., LTD. (JP) 2021-12-09 US disclosed
US-20210155612-A1 Alpha,Beta-UNSATURATED AMIDE COMPOUND KYOWA KIRIN CO., LTD. (JP) 2021-05-27 US disclosed
CN-112041296-A Aminoacetamides containing benzo-oxy-alicyclic structure and use thereof 上海璃道医药科技有限公司 2020-12-04 CN disclosed
US-10787428-B2 α,β-unsaturated amide compound KYOWA KIRIN CO., LTD. (JP) 2020-09-29 US disclosed
EP-3712129-A1 ALPHA, BETA-UNSATURATED AMIDE COMPOUND Kyowa Kirin Co., Ltd. (JP) 2020-09-23 EP disclosed
CN-110770211-A α unsaturated amide compound 协和麒麟株式会社 2020-02-07 CN disclosed
US-20190010136-A1 ALPHA,BETA-UNSATURATED AMIDE COMPOUND KYOWA HAKKO KIRIN CO., LTD. (JP) 2019-01-10 US disclosed
EP-3401309-A1 a, ß UNSATURATED AMIDE COMPOUND Kyowa Hakko Kirin Co., Ltd. (JP) 2018-11-14 EP disclosed
US-20100298306-A1 (1,4-Diaza-bicyclo[3.2.2]non-6-en-4-yl)-heterocyclyl-methanone Ligands for Nicotinic Acetylcholine Receptors, Useful for the Treatment of Disease MEMORY PHARMACEUTICALS CORPORATION (US) 2010-11-25 US disclosed
EP-2212321-A2 (1,4-DIAZA-BICYCLO[3.2.2]NON-6-EN-4-YL)-HETEROCYCLYL-METHANONE LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTORS, USEFUL FOR THE TREATMENT OF DISEASE Memory Pharmaceuticals Corporation (US) 2010-08-04 EP disclosed
WO-2009055437-A9 (1,4-DIAZA-BICYCLO[3.2.2]NON-6-EN-4-YL)-HETEROCYCLYL-METHANONE LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTORS, USEFUL FOR THE TREATMENT OF DISEASE MEMORY PHARM CORP (US) 2009-07-23 WO disclosed
WO-2009055437-A2 (1,4-DIAZA-BICYCLO[3.2.2]NON-6-EN-4-YL)-HETEROCYCLYL-METHANONE LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTORS, USEFUL FOR THE TREATMENT OF DISEASE MEMORY PHARMACEUTICALS CORPORATION (US) 2009-04-30 WO disclosed
US-4086240-A 1-Thiazolyl-5-phenoxy and phenylthioalkanoyloxyimidazolidinones VELSICOL CHEMICAL CORPORATION (US) 1978-04-25 US disclosed
US-4053480-A 1-THIADIAZOLYL-5-PHENOXY- AND PHENYLTHIOALKANOYLOXY IMIDAZOLIDINONES VELSICOL CHEMICAL CORPORATION (US) 1977-10-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210155612-A1 Alpha,Beta-UNSATURATED AMIDE COMPOUND NR1H2, NR1H3, RXRA LMNA 1763/4885SMN1; SMN2 796/4885POLB 3236/4885
US-11447471-B2 α,β-unsaturated amide compound NR1H2, RXRA, RXRB LMNA 1918/4885SMN1; SMN2 813/4885POLB 3412/4885
US-10787428-B2 α,β-unsaturated amide compound NR1H2, NCOA1, NR0B1 LMNA 2043/4885SMN1; SMN2 864/4885POLB 3134/4885
US-20100298306-A1 (1,4-Diaza-bicyclo[3.2.2]non-6-en-4-yl)-heterocyclyl-methanone Ligands for Nicotinic Acetylcholine Receptors, Useful for the Treatment of Disease CHRNA7, CHRNA6, CHRNA5 LMNA 1274/4885SMN1; SMN2 881/4885POLB 3742/4885
US-20210380551-A1 ALPHA,BETA-UNSATURATED AMIDE COMPOUND NR1H2, NR1H3, NCOA1 LMNA 1785/4885SMN1; SMN2 845/4885POLB 2972/4885
US-11332455-B2 α,β-unsaturated amide compound NR1H2, NCOA1, NR0B1 LMNA 2043/4885SMN1; SMN2 864/4885POLB 3134/4885
US-20190010136-A1 ALPHA,BETA-UNSATURATED AMIDE COMPOUND NR1H2, NR1H3, NCOA1 LMNA 1785/4885SMN1; SMN2 845/4885POLB 2972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.